ArticlePloS one2018
Metabolic syndrome in Xinjiang Kazakhs and construction of a risk prediction model for cardiovascular disease risk.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 14 citations in OpenAlex.
- Trajectories of healthy lifestyles score and cardiovascular disease: a cohort study.Family medicine and community health · 2026Article
- Environmental and ethnic differences in short-term risk of first acute myocardial infarction: a prospective multiethnic cohort protocol.Frontiers in public health · 2026Article
- Artificial Neural Networks to Predict Metabolic Syndrome without Invasive Methods in Adolescents.Journal of clinical medicine · 2024Article
- Machine learning identifies prominent factors associated with cardiovascular disease: findings from two million adults in the Kashgar Prospective Cohort Study (KPCS).Global health research and policy · 2022Article
- Prevalence and associated factors for climatic droplet keratopathy in Kazakhs adults: a cross-sectional study in Tacheng, Xinjiang, China.BMC ophthalmology · 2021Article
- Correction: Metabolic syndrome in Xinjiang Kazakhs and construction of a risk prediction model for cardiovascular disease risk.PloS one · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
18 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe high prevalence of metabolic syndrome (MetS) and cardiovascular diseases (CVD) is observed among Kazakhs in Xinjiang. Because MetS may significantly predict the occurrence of CVD, the inclusion of CVD-related indicators in metabolic network may improve the predictive ability for a CVD-risk model for Kazakhs in Xinjiang.
methodsThe study included 2,644 subjects who were followed for 5 years or longer. CVD cases were identified via medical records of the local hospitals from April 2016 to August 2017. Factor analysis was performed in 706 subjects (267 men and 439 women) with MetS to extract CVD-related potential factors from 18 biomarkers tested in a routine health check-up, served as a synthetic predictor (SP). We evaluated the predictive ability of the CVD-risk model using age and SP, logistic regression discrimination for internal validation (n = 384; men = 164, women = 220) and external validation (n = 219; men = 89, women = 130), calculated the probability of CVD for each participant, and receiver operating characteristic curves.
resultsAccording to the diagnostic criteria of JIS, the prevalence of MetS in Kazakh was 30.9%. Seven potential factors with a similar pattern were obtained from men and women and comprised the CVD predictors. When predicting CVD in the internal validation, the area under the curve (AUC) were 0.857 (95%CI 0.807-0.898) for men and 0.852 (95%CI 0.809-0.889) for women, respectively. In the external validation, the AUC to predict CVD were 0.914 (95%CI 0.832-0.963) for men and 0.848 (95%CI 0.774-0.905) for women. It is suggested that SP might serve as a useful tool in identifying CVD with in Kazakhs, especially for Kazakhs men.
conclusionsAmong 7 potential factors were extracted from 18 biomarkrs in Kazakhs with MetS, and SP may be used for CVD risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.